A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)

NCT07592819 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

367

Enrollment

OTHER

Sponsor class

Conditions

Pancreas Adenocarcinoma (MSI-H)
Pancreatic Cancer Resectable

Interventions

DRUG: mFOLFIRINOX (modified FOLFIRINOX)

Sponsor

Institut Paoli-Calmettes

Collaborators

[object Object]